2.Progress of serogroup B meningococcal outer membrane vesicle vaccines.
Meng Meng YUE ; Juan XU ; Li XU ; Zhu Jun SHAO
Chinese Journal of Preventive Medicine 2022;56(9):1333-1340
This research and development of MenB meningococcal vaccines includes two technical routes: outer membrane vesicle (OMV) vaccines and recombinant protein vaccines. This article intends to review the development, production and application of MenB meningococcal OMV vaccines in order to provide a reference for the development of MenB meningococcal OMV vaccine in China.
Antigens, Bacterial
;
Humans
;
Meningococcal Infections/prevention & control*
;
Meningococcal Vaccines
;
Neisseria meningitidis, Serogroup B
;
Serogroup
;
Vaccines, Synthetic
3.Experts' consensus on immunization with meningococcal vaccines in China.
Chinese Journal of Epidemiology 2019;40(2):123-128
Meningococcal vaccines in the Chinese market include meningococcal polysaccharide vaccine, meningococcal polysaccharide conjugate vaccine, and a combined vaccine. Meningococcal conjugate vaccines immunization schedules vary by vaccine manufacturer, and often cause confusion in immunization practices. Based on the epidemiological characteristics of meningococcal disease, serogroup distribution of Neisseria meningitidis, and research progress on the immunogenicity and safety of meningococcal vaccines, we developed an experts' consensus on immunization with meningococcal vaccines to provide guidance for immunization providers and for centers for disease control and prevention staff.
China
;
Consensus
;
Humans
;
Immunization
;
Meningococcal Infections/prevention & control*
;
Meningococcal Vaccines/administration & dosage*
;
Vaccines, Conjugate
4.Investigation on the carriage prevalence of Neisseria meningitidis in healthy population in Jiangsu Province in 2019 and 2020.
Qiang CHEN ; Yan XU ; Xiang SUN ; Yun WU
Chinese Journal of Preventive Medicine 2023;57(2):236-240
In order to investigate carriage status and serum groups distribution of Neisseria meningitidis(Nm) among healthy population in Jiangsu Province, four counties were selected as monitoring sites by random sampling method for cross-sectional study. Throat swab specimens were collected from four monitoring sites in October to November 2019 and November to December 2020 for bacterial culture and Real-time PCR detection. Chi-square test was used to compare the positive rate of Neisseria meningitidis, and multiple logistic regression model was used to analyze the influencing factors of Neisseria meningitidis carrier rate. The results showed that among 1 512 samples, 57 strains of Nm were isolated, and the carrier rate was 3.77%. Serogroup B was the dominant group (36.84%), followed by un-known serogroups (33.33%), serogroup C was the third (17.54%), serogroup W135 and serogroup A were 7.02% and 5.26%, respectively. The carriage rate (8.60%) of 15-20 years old was significantly higher than others (1.77%-3.74%)(Pearson χ2=18.211, P<0.05). Region, age and immunization history were risk factors for Neisseria meningitidis carrier rate. In summary, the Nm carrier rate of healthy population in Jiangsu Province is relatively low, which indicates that the epidemic cases will continue to be sporadic in the future. However, the prevention and control of meningococcal epidemics on campus should be strengthened, and the monitoring of neisseria meningitidis group B should be maintained as it has become the dominant epidemic strain.
Humans
;
Adolescent
;
Young Adult
;
Adult
;
Neisseria meningitidis
;
Meningococcal Infections/prevention & control*
;
Prevalence
;
Cross-Sectional Studies
;
Carrier State/microbiology*
5.Peptide Mimotopes of Neisseria meningitidis Group B Capsular Polysaccharide.
Inho PARK ; In Hong CHOI ; Se Jong KIM ; Jeon Soo SHIN
Yonsei Medical Journal 2004;45(4):755-758
The antigenic similarity between Neisseria meningitidis group B (NMGB) capsular polysaccharide (PS) and human polysialic acid (PSA) has hampered the development of a NMGB PS-based vaccine. But the possibility of a safe vaccine based on NMGB PS has been demonstrated by the existence of the NMGB PS-associated nonautoreactive epitope, which is distinct from those present on human PSA. To obtain peptide mimotopes of NMGB PS, we used HmenB3, a protective and nonautoreactive monoclonal antibody, to screen a phage library with 12 amino acids. We obtained 23 phage clones that bound to HmenB3 but not in the presence of E. coli K1 PS [which is alpha (2-8) -linked PSA like NMGB PS]. The clones contained 3 mimotopes and differed from previously described NMGB PS mimotopes. Immunization with a synthetic peptide of one mimotope elicited anti-NMGB antibodies in BALB/c mice. These mimotopes may be useful in the development of group B meningococcal vaccines.
Amino Acid Sequence
;
Animals
;
Bacterial Vaccines/*immunology
;
Cloning, Molecular
;
Female
;
Meningococcal Infections/*immunology/*prevention & control
;
Mice
;
Mice, Inbred BALB C
;
Molecular Sequence Data
;
Neisseria meningitidis, Serogroup B/genetics/*immunology
;
Polysaccharides, Bacterial/genetics/*immunology
;
Research Support, Non-U.S. Gov't